Getting at the crux of the antigen

Abstract

Novartis researchers have used structure-based antigen design to guide the rational optimization of candidate vaccines for RSV and GBS. Although the technique is not new, the work represents proof of concept for its application to the development of more effective vaccines for important pathogens.